Dalbavancin



Dalbavancin
Identifiers
CAS number
PubChem 16134410
Properties
Molecular formula O28
Molar mass 1816.6918
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Dalbavancin, a novel second-generation lipoglycopeptide agent, belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with MRSA.[1]

It possesses in vitro activity against a variety of gram-positive pathogens[2][3] including MRSA and MRSE. [4]It is a once-weekly, two-dose Vicuron Pharmaceuticals in 2005.[5]

References and notes

  1. ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
  2. ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMID 17362476.
  3. ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524.
  4. ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
  5. ^ UPDATE 1-Pfizer says US FDA wants more data on antibiotic
v • d • e
Hitachimycin - Dalbavancin - Telavancin
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dalbavancin". A list of authors is available in Wikipedia.